Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Neratinib
Drug: Trastuzumab
Drug: Paclitaxel

First Posted Date: 2009-06-05

Last Posted Date: 2018-08-22

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 479

Registration Number: NCT00915018

Locations: 🇫🇷
Service d'Oncologie et de Radiotherapie, Polyclinique Francheville, Perigueux, France
🇷🇴
Institutul Oncologic Prof. Dr. Ion Chiricuţă, Cluj-Napoca, Cluj, Romania
🇪🇸
Hospital Universitario Fundación Alcorcón, Alcorcon, Madrid, Spain

and more 191 locations

Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence

Phase 2

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Radiation: Proton Therapy
Radiation: Photon Therapy
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-06-05

Last Posted Date: 2020-05-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 275

Registration Number: NCT00915005

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

Phase 1

Completed

Conditions: Neoplasms
Breast Cancer
Breast Neoplasms

Interventions: Drug: AZD8931
Drug: Paclitaxel
Drug: Placebo

First Posted Date: 2009-05-13

Last Posted Date: 2016-01-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 330

Registration Number: NCT00900627

Locations: 🇬🇧
Research Site, Surrey, United Kingdom

Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel

Completed

Conditions: Lung Cancer

First Posted Date: 2009-05-12

Last Posted Date: 2017-05-19

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 180

Registration Number: NCT00900172

Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab

Completed

Conditions: Lung Cancer

First Posted Date: 2009-05-12

Last Posted Date: 2017-05-19

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 90

Registration Number: NCT00898417

Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344

Completed

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel
Genetic: fluorescence in situ hybridization
Other: immunohistochemistry staining method

First Posted Date: 2009-05-12

Last Posted Date: 2021-08-17

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 1195

Registration Number: NCT00897026

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: ABT-263
Drug: paclitaxel

First Posted Date: 2009-05-01

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 19

Registration Number: NCT00891605

Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Adult Grade III Lymphomatoid Granulomatosis
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Contiguous Stage II Adult Burkitt Lymphoma
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma
Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Contiguous Stage II Adult Lymphoblastic Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma
Contiguous Stage II Grade 2 Follicular Lymphoma

Interventions: Drug: R-(-)-gossypol acetic acid
Drug: paclitaxel
Drug: carboplatin
Other: pharmacological study

First Posted Date: 2009-04-30

Last Posted Date: 2013-01-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00891072

Locations: 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Phase 1

Completed

Conditions: Solid Tumors
Ovarian Cancer

Interventions: Drug: OSI-906
Drug: Paclitaxel

First Posted Date: 2009-04-28

Last Posted Date: 2024-11-20

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 152

Registration Number: NCT00889382

Locations: 🇷🇴
Clinical Caunty Hospital Mures, Mures, Romania
🇨🇿
General University Hospital, Department of Obstetrics and Gynecology, Prague, Czechia
🇷🇴
Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia de Oncologie Medicala, Cluj Napoca, Romania

and more 43 locations

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Ovarian Transitional Cell Tumor
Fallopian Tube Transitional Cell Carcinoma
Ovarian Seromucinous Carcinoma
Ovarian Serous Adenocarcinoma
Ovarian Brenner Tumor
Ovarian Mucinous Adenocarcinoma
Fallopian Tube Serous Adenocarcinoma
Fallopian Tube Undifferentiated Carcinoma
Ovarian Clear Cell Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma

Interventions: Drug: Elesclomol Sodium
Drug: Paclitaxel

First Posted Date: 2009-04-27

Last Posted Date: 2021-10-20

Lead Sponsor: GOG Foundation

Target Recruit Count: 58

Registration Number: NCT00888615

Locations: 🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States
🇺🇸
Regional Cancer Center at Indian Path Community Hospital, Kingsport, Tennessee, United States
🇺🇸
Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States

and more 160 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy